[go: up one dir, main page]

FI20090384L - Förfarande för framställning av en modifierad G-CSF-polypeptid - Google Patents

Förfarande för framställning av en modifierad G-CSF-polypeptid Download PDF

Info

Publication number
FI20090384L
FI20090384L FI20090384A FI20090384A FI20090384L FI 20090384 L FI20090384 L FI 20090384L FI 20090384 A FI20090384 A FI 20090384A FI 20090384 A FI20090384 A FI 20090384A FI 20090384 L FI20090384 L FI 20090384L
Authority
FI
Finland
Prior art keywords
preparing
modified
csf polypeptide
csf
polypeptide
Prior art date
Application number
FI20090384A
Other languages
English (en)
Finnish (fi)
Other versions
FI123078B (sv
Inventor
Timothy D Osslund
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21743861&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI20090384(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of FI20090384L publication Critical patent/FI20090384L/sv
Application granted granted Critical
Publication of FI123078B publication Critical patent/FI123078B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
FI20090384A 1993-01-28 2009-10-21 Förfarande för framställning av en modifierad G-CSF-polypeptid FI123078B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/010,099 US5581476A (en) 1993-01-28 1993-01-28 Computer-based methods and articles of manufacture for preparing G-CSF analogs
US1009993 1993-01-28
PCT/US1994/000913 WO1994017185A1 (en) 1993-01-28 1994-01-25 G-csf analog compositions and methods
US9400913 1994-01-25

Publications (2)

Publication Number Publication Date
FI20090384L true FI20090384L (sv) 2009-10-21
FI123078B FI123078B (sv) 2012-10-31

Family

ID=21743861

Family Applications (2)

Application Number Title Priority Date Filing Date
FI953593A FI120769B (sv) 1993-01-28 1995-07-27 G-CSF-analogkompositioner och förfaranden
FI20090384A FI123078B (sv) 1993-01-28 2009-10-21 Förfarande för framställning av en modifierad G-CSF-polypeptid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI953593A FI120769B (sv) 1993-01-28 1995-07-27 G-CSF-analogkompositioner och förfaranden

Country Status (21)

Country Link
US (6) US5581476A (sv)
EP (8) EP0890640A3 (sv)
JP (7) JPH08506018A (sv)
KR (2) KR100375274B1 (sv)
CN (3) CN1118572C (sv)
AT (2) ATE553199T1 (sv)
AU (2) AU697451B2 (sv)
CA (4) CA2711007C (sv)
DE (1) DE69425516T2 (sv)
DK (3) DK2345724T3 (sv)
ES (3) ES2150951T3 (sv)
FI (2) FI120769B (sv)
GR (1) GR3034745T3 (sv)
IL (6) IL145994A (sv)
LU (1) LU92265I2 (sv)
LV (1) LV12642B (sv)
NO (3) NO952974L (sv)
NZ (5) NZ314960A (sv)
PT (3) PT2345724E (sv)
WO (1) WO1994017185A1 (sv)
ZA (1) ZA94568B (sv)

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006952A1 (fr) * 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US20020177688A1 (en) * 1988-12-22 2002-11-28 Kirin-Amgen, Inc., Chemically-modified G-CSF
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JP3708151B2 (ja) * 1994-12-15 2005-10-19 協和醗酵工業株式会社 Ｐｅｇ化したヒト顆粒球コロニー刺激因子の定量法
CA2244228A1 (en) * 1996-01-22 1997-07-24 Creative Biomolecules, Inc. Morphogen analogs and methods for producing them
US20030185792A1 (en) * 1996-01-22 2003-10-02 Curis, Inc. Morphogen analogs of bone morphogenic proteins
US5835382A (en) * 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
US6128582A (en) * 1996-04-30 2000-10-03 Vertex Pharmaceuticals Incorporated Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them
CA2296770A1 (en) * 1997-07-14 1999-01-28 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US6017876A (en) 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
CN1061992C (zh) * 1997-11-19 2001-02-14 蒋永平 新的重组人粒细胞集落刺激因子及其药物组合物
TWI242563B (en) * 1998-04-30 2005-11-01 Tanox Inc Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor
KR100479790B1 (ko) * 1998-04-30 2005-03-30 타녹스 인코퍼레이티드 G - c s f 수용체의 항진 항체 및 이를 스크리닝하는 방법
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
CA2357811A1 (en) * 1999-01-06 2000-07-13 Xencor, Inc. Nucleic acids and proteins corresponding to mutants of g-csf with granulopoietic activity
US7208473B2 (en) * 1999-01-06 2007-04-24 Xencor, Inc. Nucleic acids and protein variants of hG-CSF with granulopoietic activity
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
DE60004172T2 (de) * 1999-01-29 2004-04-22 F. Hoffmann-La Roche Ag Gcsf konjugate
US6500418B1 (en) * 1999-02-12 2002-12-31 The Washington University Stimulating neutrophil function to treat inflammatory bowel disease
JP2000319298A (ja) * 1999-03-04 2000-11-21 Seibutsu Bunshi Kogaku Kenkyusho:Kk 蛋白質複合体の結晶、構造座標、及び構造座標の使用
US7244396B2 (en) 1999-04-06 2007-07-17 Uab Research Foundation Method for preparation of microarrays for screening of crystal growth conditions
US20030022383A1 (en) * 1999-04-06 2003-01-30 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US7214540B2 (en) * 1999-04-06 2007-05-08 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
EP1181548B1 (en) * 1999-04-06 2007-03-21 The University of Alabama at Birmingham Research Foundation Method for screening crystallization conditions in solution crystal growth
US7247490B2 (en) 1999-04-06 2007-07-24 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US7250305B2 (en) 2001-07-30 2007-07-31 Uab Research Foundation Use of dye to distinguish salt and protein crystals under microcrystallization conditions
AU4835200A (en) * 1999-05-10 2000-11-21 Regents Of The University Of California, The Methods and compositions for controlled polypeptide synthesis
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
US6296673B1 (en) * 1999-06-18 2001-10-02 The Regents Of The University Of California Methods and apparatus for performing array microcrystallizations
US7058517B1 (en) 1999-06-25 2006-06-06 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
CA2379388C (en) * 1999-07-13 2012-05-29 George N. Cox, Iii Immunoglobulin fusion proteins
US8106098B2 (en) * 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
KR100773323B1 (ko) * 2000-01-10 2007-11-05 맥시겐 홀딩스 리미티드 지-씨에스에프 접합체
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6831158B2 (en) * 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
GB0008563D0 (en) * 2000-04-07 2000-05-24 Cambridge Discovery Chemistry Investigating different physical and/or chemical forms of materials
PT1043239E (pt) * 2000-06-16 2004-05-31 Vsi Holding As Recipiente com lados colapsaveis
US6931326B1 (en) 2000-06-26 2005-08-16 Genaissance Pharmaceuticals, Inc. Methods for obtaining and using haplotype data
US7792645B2 (en) * 2000-08-30 2010-09-07 The Salk Institute For Biological Studies Three-dimensional structure of chalcone isomerase and methods of use thereof
EP1354045A2 (en) * 2000-09-07 2003-10-22 Eli Lilly And Company Hyperglycosylated polypeptides
MXPA03002046A (es) * 2000-09-08 2003-07-24 Massachusetts Inst Technology Composiciones analogos de factor estimulador de colonias de granulocitos y metodos para su elaboracion.
EP1334127A1 (en) * 2000-11-02 2003-08-13 Maxygen Aps Single-chain multimeric polypeptides
JP2005502099A (ja) * 2001-03-12 2005-01-20 ボード オブ レジェンツ，ザ ユニバーシティー オブ テキサス システム タンパク質医薬品デザインのためのアンサンブルベースのストラテジー
DE10112825A1 (de) * 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
US7670429B2 (en) 2001-04-05 2010-03-02 The California Institute Of Technology High throughput screening of crystallization of materials
US6998219B2 (en) * 2001-06-27 2006-02-14 University Of South Florida Maskless photolithography for etching and deposition
EP1425304B9 (en) 2001-07-11 2010-09-08 Maxygen, Inc. G-csf conjugates
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US20040247562A1 (en) * 2001-09-28 2004-12-09 Sang Yup Lee Diagnostic method for cancer characterized in the detection of the deletion of g-csf exon 3
DE10209821A1 (de) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
AU2003241565A1 (en) * 2002-05-23 2003-12-12 Board Of Regents, The University Of Texas System Predicting the significance of single nucleotide polymorphisms (snps) using ensemble-based structural energetics
AU2003256469A1 (en) * 2002-07-10 2004-01-23 Uab Research Foundation Method for distinguishing between biomolecule and non-biomolecule crystals
WO2004022593A2 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
DE10242076A1 (de) * 2002-09-11 2004-03-25 Fresenius Kabi Deutschland Gmbh HAS-Allergen-Konjugate
RU2328505C2 (ru) * 2002-09-11 2008-07-10 Фрезениус Каби Дойчланд Гмбх Полипептиды, обработанные has, особенно эритропоэтин, обработанный has
WO2004032971A1 (en) * 2002-10-08 2004-04-22 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
JP5207590B2 (ja) * 2002-12-26 2013-06-12 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド 増強された生物学的能力を有するインターフェロン−βのポリマー結合体
US20040136952A1 (en) * 2002-12-26 2004-07-15 Mountain View Pharmaceuticals, Inc. Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
US7785601B2 (en) 2002-12-31 2010-08-31 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
US7695723B2 (en) 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
DK1648931T3 (da) 2003-07-21 2011-03-07 Transgene Sa Multifunktionelle cytokiner
EP1653991A2 (en) * 2003-08-08 2006-05-10 Fresenius Kabi Deutschland GmbH Conjugates of a polymer and a protein linked by an oxime linking group
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US20090226397A1 (en) * 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
EP2198875A1 (en) * 2003-10-24 2010-06-23 Nora, LLC A method for reducing the likelihood of preterm labour in a subject in need thereof
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
US7220407B2 (en) * 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
US20060122784A1 (en) * 2004-12-03 2006-06-08 Ishikawa Muriel Y System and method for augmenting a humoral immune response
EP2286791B1 (en) 2003-12-30 2014-03-26 Durect Corporation Polymeric implants, preferably containing a mixture of PEG and PLG, for controlled release of active agents
EP2336192A1 (en) 2004-03-11 2011-06-22 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
TW200603818A (en) * 2004-03-11 2006-02-01 Fresenius Kabi De Gmbh Conjugates of hydroxyethyl starch and erythropoietin
CN101031655A (zh) 2004-07-26 2007-09-05 陶氏环球技术公司 通过株工程改进蛋白表达的方法
ATE544463T1 (de) 2004-11-05 2012-02-15 Univ Northwestern Verwendung von scf und g-scf bei der behandlung von hirnischämie und neurologischen störungen
US7741096B2 (en) * 2004-12-10 2010-06-22 Genentech, Inc. Crystal structure of hepatocyte growth factor activator complexed with Kunitz domain inhibitor
EP1828241A1 (en) 2004-12-23 2007-09-05 Laboratoires Serono S.A. G-csf polypeptides and uses thereof
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
KR100657749B1 (ko) * 2005-04-13 2006-12-20 씨제이 주식회사 인간 과립구 콜로니 형성인자 동종체 및 그 조성물
KR20080027291A (ko) 2005-06-01 2008-03-26 맥시겐 홀딩스 엘티디 피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법
KR100694994B1 (ko) * 2005-06-13 2007-03-14 씨제이 주식회사 사람 과립구 콜로니 형성인자 동종체
KR100735784B1 (ko) 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
CN101243032B (zh) * 2005-08-15 2012-10-10 法雷斯药品研究公司 虾青素的晶型
US8017315B2 (en) * 2005-08-22 2011-09-13 Dana Farber Cancer Institute, Inc. Mitochondrial localization of MUC1
US20070112804A1 (en) * 2005-11-07 2007-05-17 Desimas Bruce E Systems and methods for generating automated software workflows for biological testing
GB0605684D0 (en) * 2006-03-21 2006-05-03 Sicor Biotech Uab Method For Purifying Granulocyte-Colony Stimulating Factor
US8129345B2 (en) * 2006-07-20 2012-03-06 Dana-Farber Cancer Institute, Inc. MUC1-IκB kinase complexes and their activities
US7871784B2 (en) * 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
WO2008097840A2 (en) 2007-02-02 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
JP4375412B2 (ja) * 2007-02-19 2009-12-02 株式会社デンソー 蒸発器ユニット
WO2008134461A2 (en) 2007-04-27 2008-11-06 Dow Global Technologies, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
MX2010000143A (es) * 2007-07-03 2012-09-19 Amgen Inc Medicion de proteinas utilizando el peso seco de cuerpos de inclusion.
SG10202005450PA (en) 2007-07-09 2020-07-29 Genentech Inc Prevention of disulfide bond reduction during recombinant production of polypeptides
EP2581441A1 (en) 2007-08-09 2013-04-17 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
US8758761B2 (en) * 2007-09-30 2014-06-24 University Of Florida Research Foundation, Inc. Combination therapies for treating type 1 diabetes
US8570393B2 (en) * 2007-11-30 2013-10-29 Cognex Corporation System and method for processing image data relative to a focus of attention within the overall image
EP2070951A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Method for producing a hydroxyalkyl starch derivatives with two linkers
EP2070950A1 (en) * 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
CA2712606A1 (en) 2008-02-08 2009-08-13 Ambrx, Inc. Modified leptin polypeptides and their uses
JP5225393B2 (ja) 2008-02-18 2013-07-03 ジエンス ヘンルイ メデイシンカンパニー リミテッド 水溶性高分子修飾ｇ−ｃｓｆ複合体
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
WO2010011767A2 (en) 2008-07-22 2010-01-28 Duke Debra M Compositions and methods for treating symptoms associated with menopause, hormonal variations and arthritis
UA118536C2 (uk) 2008-07-23 2019-02-11 Амбркс, Інк. Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування
US9151289B2 (en) 2008-08-21 2015-10-06 Cummins Inc. Fuel pump
JP5878757B2 (ja) 2008-10-10 2016-03-08 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
DK2352508T3 (da) 2008-10-17 2014-04-28 Dana Farber Cancer Inst Inc Muc-1 cytoplasmisk domæne-peptider som inhibitorer af cancer
US9189670B2 (en) * 2009-02-11 2015-11-17 Cognex Corporation System and method for capturing and detecting symbology features and parameters
JP2012525847A (ja) 2009-05-05 2012-10-25 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
BRPI1011404B1 (pt) 2009-05-05 2022-05-03 Amgen Inc Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira
US8324160B2 (en) * 2009-06-17 2012-12-04 Amgen Inc. Chimeric polypeptides and uses thereof
JP2013512672A (ja) 2009-12-02 2013-04-18 アムジエン・インコーポレーテツド ヒトＦＧＦＲ１ｃ、ヒトβ−クロト−、ならびにヒトＦＧＦＲ１ｃおよびヒトβ−クロト−の両方に結合する結合タンパク質
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
EA201290541A1 (ru) 2009-12-21 2013-05-30 Амбркс, Инк. Модифицированные бычьи соматотропиновые полипептиды и их применение
EP2516455A4 (en) 2009-12-21 2013-05-22 Ambrx Inc MODIFIED SWINE SOMATOTROPIN POLYPEPTIDES AND THEIR USES
WO2011115819A2 (en) 2010-03-15 2011-09-22 Genus Oncology, Llc Small molecule inhibitors of muc1 and methods of identifying the same
JP5714692B2 (ja) 2010-03-23 2015-05-07 イーエムベーアー−インスティトゥート・フューア・モレクラレ・ビオテヒノロギー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＩｍｂａ−Ｉｎｓｔｉｔｕｔ Ｆｕｅｒｍｏｌｅｋｕｌａｒｅ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅ Ｇｍｂｈ Ｉｉｉ型分泌機構の阻害剤の同定方法
MX2012011986A (es) 2010-04-15 2013-03-05 Amgen Inc RECEPTOR FGF HUMANO Y PROTEINAS ENLAZADAS A ß-KLOTHO.
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
EP3241558B1 (en) 2010-09-28 2021-03-03 Aegerion Pharmaceuticals, Inc. Highly soluble leptins
US8889630B2 (en) 2011-12-23 2014-11-18 Carlos Lopez Method for hair regrowth using Granulocyte-Colony Stimulating Factor
WO2014045126A2 (en) 2012-09-18 2014-03-27 Uti Limited Partnership Treatment of pain by inhibition of usp5 de-ubiquitinase
PT3524618T (pt) 2013-03-15 2023-06-06 Gladiator Biosciences Inc Domínios gla como agentes de marcação
LT6161B (lt) 2013-09-27 2015-06-25 Uab Profarma Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas
WO2015057724A1 (en) 2013-10-14 2015-04-23 Nora Therapeutics, Inc. Use of g-csf for treating or preventing villitis of unknown etiology in a human female
MX2017016103A (es) * 2015-06-11 2018-05-22 Ambio Pharmaceuticals Llc Factor estimulador de colonia de granulocito (gcsf) pegilado.
EP3365360A1 (en) * 2015-10-19 2018-08-29 Sandoz AG Improved coding sequence for human g-csf
PE20201263A1 (es) 2017-09-05 2020-11-19 Gladiator Biosciences Inc Suministro de cargas utiles a las celulas madre
CN108384747A (zh) * 2018-03-05 2018-08-10 安徽省农业科学院园艺研究所 表达狂犬抗体的cho细胞无血清悬浮培养方法
CN114901684B (zh) * 2019-10-08 2025-09-09 酵活英属哥伦比亚有限公司 粒细胞集落刺激因子受体(g-csfr)的经修饰胞外结构域和结合其的细胞因子
WO2021123033A1 (en) 2019-12-17 2021-06-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel g-csf mimics and their applications

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
WO1985000817A1 (en) * 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS6263335A (ja) * 1985-09-13 1987-03-20 Fuji Photo Film Co Ltd 化学反応情報の処理方法
US4908773A (en) * 1987-04-06 1990-03-13 Genex Corporation Computer designed stabilized proteins and method for producing same
DK203187A (da) * 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
WO1988001297A1 (en) * 1986-08-11 1988-02-25 Cetus Corporation Expression of g-csf and muteins thereof
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
DK174044B1 (da) * 1986-12-23 2002-05-06 Kyowa Hakko Kogyo Kk Polypeptid afledt fra human granulocytkolonistimulerende faktor, og fremgangsmåde til fremstilling deraf, DNA kodende for nævnte polypeptid, rekombinant plasmid indeholdende nævnte DNA, og mikroorganismer indeholdende nævnte rekombinante plasmid.......
US4853871A (en) * 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
GB2213821B (en) * 1987-12-23 1992-01-02 British Bio Technology Synthetic human granulocyte colony stimulating factor gene
US5153265A (en) * 1988-01-20 1992-10-06 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
CA1340810C (en) * 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
DE68918331T2 (de) * 1988-06-03 1995-05-18 Chugai Pharmaceutical Co Ltd Menschlicher kristallinischer Granulocyt-Koloniestimulierungsfaktor und dessen Herstellung.
US5025388A (en) * 1988-08-26 1991-06-18 Cramer Richard D Iii Comparative molecular field analysis (CoMFA)
US5218092A (en) * 1988-09-29 1993-06-08 Kyowa Hakko Kogyo Co., Ltd. Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5109119A (en) * 1989-06-06 1992-04-28 Schering Corporation Crystalline r-h-gm-csf and method
US5265030A (en) * 1990-04-24 1993-11-23 Scripps Clinic And Research Foundation System and method for determining three-dimensional structures of proteins
GB9107846D0 (en) * 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) * 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
JP3249147B2 (ja) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド 生理活性蛋白含有経口製剤
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
DK0546124T4 (da) * 1990-08-29 2003-05-19 Inst Genetics Llc Hæmatopoiese-stimulatorer med flere domæner
US5124297A (en) 1990-12-07 1992-06-23 Amoco Corporation Olefin polymerization and copolymerization catalyst
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
JPH06506217A (ja) * 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
US5157736A (en) * 1991-04-19 1992-10-20 International Business Machines Corporation Apparatus and method for optical recognition of chemical graphics
US5386507A (en) * 1991-07-18 1995-01-31 Teig; Steven L. Computer graphics system for selectively modelling molecules and investigating the chemical and physical properties thereof
EP0601043B1 (en) * 1991-08-30 1998-11-25 Fred Hutchinson Cancer Research Center Hybrid cytokines
JP2638359B2 (ja) * 1991-11-26 1997-08-06 富士通株式会社 分子動力学法の拘束条件作成装置
DE69329247T2 (de) * 1992-06-09 2001-05-31 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Kristallisierung von m-csf
US6057133A (en) 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US6153183A (en) 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
US5772992A (en) 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
US5738849A (en) 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
DE69333243T2 (de) 1992-11-24 2004-08-19 G.D. Searle & Co., Chicago Mutierte polypeptide des interleukin-3(il-3)
US5424963A (en) * 1992-11-25 1995-06-13 Photon Research Associates, Inc. Molecular dynamics simulation method and apparatus
US5581476A (en) 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
EP0807181A1 (en) 1995-02-03 1997-11-19 G.D. Searle & Co. NOVEL c-MPL LIGANDS
US6017523A (en) 1995-06-06 2000-01-25 G.D. Searle & Co. Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides
CA2234042A1 (en) 1995-10-05 1997-04-10 G.D. Searle & Co. Novel g-csf receptor agonists
US6100070A (en) 1995-10-05 2000-08-08 G. D. Searle & Co. G-CSF receptor agonists
BRPI9610977A2 (pt) 1995-10-05 2019-09-17 Searle & Co agonistas receptores hematopoiéticos multi-funcionais
AU722759B2 (en) 1995-10-05 2000-08-10 G.D. Searle & Co. Novel C-MPL receptor agonists
US6066318A (en) 1995-10-05 2000-05-23 G.D. Searle & Co. Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
US5969105A (en) 1996-10-25 1999-10-19 Feng; Yiqing Stem cell factor receptor agonists
CA2268742A1 (en) 1996-10-25 1998-04-30 G.D. Searle & Co. Multi-functional chimeric hematopoietic receptor agonists
US6660257B1 (en) 1996-10-25 2003-12-09 Pharmacia Corporation Circular permuteins of flt3 ligand
WO1998046750A1 (en) 1997-04-11 1998-10-22 G.D. Searle & Co. flt3 LIGAND CHIMERIC PROTEINS
EP1115854A1 (en) 1998-09-25 2001-07-18 G.D. Searle & Co. Method of producing permuteins by scanning permutagenesis
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
ES2556338T3 (es) * 2001-10-10 2016-01-15 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos

Also Published As

Publication number Publication date
CA2711007A1 (en) 1994-08-04
IL108446A0 (en) 1994-04-12
US20030171559A1 (en) 2003-09-11
DK2345724T3 (da) 2013-09-30
NO952974D0 (no) 1995-07-27
US7381804B2 (en) 2008-06-03
US6632426B2 (en) 2003-10-14
EP0965638A2 (en) 1999-12-22
NZ504840A (en) 2001-11-30
EP0612846A1 (en) 1994-08-31
FI120769B (sv) 2010-02-26
ATE195552T1 (de) 2000-09-15
NZ261765A (en) 1997-10-24
IL145994A0 (en) 2002-07-25
CN1495197A (zh) 2004-05-12
DE69425516T2 (de) 2001-06-13
JP2010059170A (ja) 2010-03-18
EP1482045A2 (en) 2004-12-01
EP0965638A3 (en) 2000-02-23
NZ314960A (en) 1999-01-28
IL125398A0 (en) 1999-03-12
EP1482046A2 (en) 2004-12-01
JP2009057368A (ja) 2009-03-19
IL124111A (en) 2002-09-12
DK1482046T3 (da) 2012-06-25
NZ332188A (en) 2000-07-28
EP0612846B1 (en) 2000-08-16
IL108446A (en) 2003-01-12
KR100390338B1 (ko) 2003-07-07
ZA94568B (en) 1994-09-12
CA2153896A1 (en) 1994-08-04
IL145994A (en) 2010-12-30
AU8197098A (en) 1998-10-15
NO20031497D0 (no) 2003-04-02
ES2382927T3 (es) 2012-06-14
CA2381489A1 (en) 1994-08-04
EP1482045A3 (en) 2004-12-29
PT612846E (pt) 2001-01-31
NO952974L (no) 1995-09-28
US5581476A (en) 1996-12-03
JP2006137762A (ja) 2006-06-01
EP0890640A3 (en) 1999-03-24
CN1970571A (zh) 2007-05-30
AU697451B2 (en) 1998-10-08
IL124112A (en) 2006-12-10
CA2153896C (en) 1999-01-12
HK1107356A1 (en) 2008-04-03
KR100375274B1 (ko) 2003-06-11
ES2422269T3 (es) 2013-09-10
WO1994017185A1 (en) 1994-08-04
CA2239360A1 (en) 1994-08-04
LV12642B (en) 2001-09-20
NZ513422A (en) 2002-09-27
CN1118572C (zh) 2003-08-20
EP0974655A2 (en) 2000-01-26
US5790421A (en) 1998-08-04
JP2006096762A (ja) 2006-04-13
ATE553199T1 (de) 2012-04-15
CN1132527A (zh) 1996-10-02
PT1482046E (pt) 2012-06-06
KR960700341A (ko) 1996-01-19
JPH08506018A (ja) 1996-07-02
LU92265I2 (fr) 2013-10-14
CA2711007C (en) 2012-10-02
DE69425516D1 (de) 2000-09-21
US20010016191A1 (en) 2001-08-23
LV12642A (lv) 2001-04-20
CA2381489C (en) 2010-10-19
US8058398B2 (en) 2011-11-15
NO20031497L (no) 2003-04-02
JP2011207885A (ja) 2011-10-20
FI123078B (sv) 2012-10-31
DK0612846T3 (da) 2000-10-09
PT2345724E (pt) 2013-08-22
EP0974655A3 (en) 2001-10-24
ES2150951T3 (es) 2000-12-16
CA2239360C (en) 2002-07-16
EP2345724A1 (en) 2011-07-20
US20050260154A1 (en) 2005-11-24
HK1009288A1 (en) 1999-05-28
CN1495197B (zh) 2013-01-16
US6261550B1 (en) 2001-07-17
EP1482046A3 (en) 2005-01-05
JP2004113243A (ja) 2004-04-15
EP2345724B1 (en) 2013-07-03
FI953593L (sv) 1995-07-27
NO20093489L (no) 1995-09-28
EP1233065A1 (en) 2002-08-21
FI953593A0 (sv) 1995-07-27
GR3034745T3 (en) 2001-02-28
EP0890640A2 (en) 1999-01-13
EP1482046B1 (en) 2012-04-11
CN1970571B (zh) 2013-07-10
AU6095794A (en) 1994-08-15

Similar Documents

Publication Publication Date Title
FI20090384L (sv) Förfarande för framställning av en modifierad G-CSF-polypeptid
FI962069L (sv) Förfarande för framställning av karpolaktam
FI933357A7 (sv) Förfarande för framställning av benzamider
FI922938A0 (sv) Förfarande för att effektivera kanalväxling
FI961071L (sv) Förfarande för framställning av zeolit
FI891480A7 (sv) Förfarande för framställning av fotohärdbara beläggningar
FI891711L (sv) Förfarande för framställning av diorganodialkoxisilaner
FI925988A7 (sv) Förfarande för framställning av B-laktamer
FI933677A7 (sv) Förfarande för framställning av kompositsorbent
FI924051A7 (sv) Förfarande för framställning av mellandestillat
FI943703L (sv) Förfarande för framställning av gamma-butyrolakton
FI942907L (sv) Förfarande för framställning av lipas
FI955800L (sv) Metod att framställa aminoalkylguanidiner
FI921621L (fi) Sprutmetod foer braensle
FI920861A7 (sv) Förfarande för framställning av antitrombiniska polypeptider
FI19992039L (sv) Förfarande för framställning av azepinoner
FI931850L (sv) Foerfarande foer framstaellning av en mellanprodukt
FI20001776A7 (sv) Förfarande för framställning av farmaceutisk komposition
FI942102L (sv) Förfarande för framställning av aluminoxaner
FI960429L (sv) Förfarande för framställning av 1,4-butandiol
FI891362A7 (sv) Förfarande för framställning av nya alkanofenoner
FI895800A7 (sv) Förfarande för framställning av nya a-cyano-b-oxopropionamider
FI962046L (sv) Förfarande för framställning av gamma-butyrolakton
FI932126A7 (sv) Förfarande för framställning av 2-klor-5-klormetylpyridin
DK44593D0 (da) Fremgangsmaade til fremstilling af et polypeptid

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 123078

Country of ref document: FI

Kind code of ref document: B

MA Patent expired